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Endothelial Cell Mediators of Angiogenesis in Bartonella henselae Infection
Amy M. McCord
ABSTRACT

Bacillary angiomatosis (BA), one of the clinical manifestations resulting from
infection with the facultative intracellular bacterium Bartonella henselae, is characterized
by angiogenic lesions. Endothelial cells have been identified as host cells for this
pathogen and are presumed important for pathogenesis as lesions contain bacteria in
direct contact with the endothelium. Lesions also contain infiltrating macrophages,
which contribute to the angiogenic process during B. henselae infection by secreting
vascular endothelial growth factor (VEGF). While virulence factors have been
characterized, and the role for macrophages in B. henselae infection has been established,
endothelial cell mediators of angiogenesis have not been well defined. We investigated
three potentially important pathways that are triggered by the bacterial interactions with
endothelial cells. We examined the ability of endothelial cells to upregulate the
chemokines monocyte-macrophage chemoattractant protein-1 (MCP-1) and CXCL8 and
the mechanism by which B. henselae secreted proteins (BHSP) induce endothelial cell
proliferation. We determined that MCP-1 production is upregulated in response to B.
henselae infection, which very likely contributes to angiogenic lesion formation by
recruiting the VEGF-secreting macrophage. The chemokine CXCL8 is an important
mediator of angiogenesis which can cause endothelial cell survival, proliferation, and
vii

capillary tube formation. We determined that CXCL8 is secreted from B. henselaeinfected cells and contributes to B. henselae-induced angiogenesis in an autocrine
manner. We also investigated the role of Ca2+ signaling during B. henselae infection.
We determined that BHSP induce a robust intracellular Ca2+ response in HUVEC which
originates from intracellular Ca2+ pools. Additionally, endothelial cell proliferation in
response to BHSP required Ca2+ activity, indicating a role for intracellular Ca2+ pools
during B. henselae-induced angiogenesis. Endothelial cell proliferation during B.
henselae infection possibly indicates a mechanism by which a pathogen induces
proliferation of its host cell in order to propagate its own survival. Numerous factors
culminate in the vascular lesions that are characteristic of BA. B. henselae infection
represents an important and unique model for pathogen-triggered angiogenesis, and
studies into the specific mechanisms of this process may elucidate host cell-pathogen
interactions as well as pathways of pathogenic angiogenesis.
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Introduction

Bartonella Species and Human Disease
Bartonellae are short, pleomorphic, gram negative rods which are fastidious,
aerobic, oxidase negative organisms (4). They are classified within the α2 subgroup of
the class proteobacteria. The single genus Bartonella was created by merging B.
bacilliformis and the genus Rochalimaea (13). There are currently 16 Bartonella spp.
identified. Figure 1 shows a parsimony tree for Bartonella species derived from 16s
rRNA sequences (37). Bartonella spp. cause a chronic intraerythrocytic bacteremia in
reservoir hosts and are transmitted by arthropod vectors during feeding. Bartonella can
cause an asymptomatic bacteremia. B. quintana, B. bacilliformis, B. elizabethae, B.
grahamii, B. vinsonii subsp. berkhoffii, B. vinsonii subsp. arupensis, B. henselae, and B.
clarridgeiae cause human disease. B. qunitana causes trench fever, a recurrent fever
transmitted by human body lice, bacteremia, and bacillary angiomatosis (BA). B.
bacilliformis causes Carrion’s disease and Orroya fever with chronic verrugae. B.
henselae causes cat scratch disease (CSD) and BA. B. quintana, B. henselae, B.
elizabethae, B. vinsonii subsp. berkhoffii, and B. vinsonii subsp. arupensis have been
associated with endocarditis, usually in patients previously diagnosed with valvulopathy
(31).
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Figure 1. Comparison of parsimony tree (left side) and neighbor-joining tree
(right side) derived from complete ITS sequences for recognized Bartonella
species (type strains). The support of each branch, as determined from
100 bootstrap samples, is indicated by the value at the node. The lengths of vertical
lines are not significant. For the parsimony tree, the lengths of horizontal lines are
also not significant. For the neighbor-joining tree, the scale bar represents
evolutionary distance as calculated by using the Kimura two-parameter distance
calculation. (37).
2

Bartonella henselae
B. henselae are gram-negative bacilli that display twitching motility. The genome
size is around 1.9 X 106 bp (3). There are two phases of B. henselae in culture: the rough
and smooth forms. The “rough” bacteria express a pilus-like structure that has been
recently characterized as Bartonella adhesion A (BadA, see Virulence factors). The
presence of pili correlates with more efficient attachment to host cells (4). The “rough”
forms autoagglutinate, pit chocolate agar, and display a dry colony morphology (9). In
contrast, the phase variation to “smooth” B. henselae, which correlates with increased
passage number, is characterized by mucoid, non-pitting colonies, no auto-agglutination,
and fewer pili (9).

Diseases Caused by Bartonella henselae
B. henselae is a flea-borne pathogen of cats and humans. Blood donors in the
USA and Australia exhibit a 3-6% seroprevalence for B. henselae (12, 19, 29, 39, 47).
Two manifestations of B. henselae infection include CSD and BA. CSD is a usually selflimiting lymphadenitis. While the lymph nodes usually regress after a period of weeks or
months, in 10% of patients the lymphadenitis may become suppurative. Additionally,
rash, hepatosplenomegaly, lytic bone lesions, and deep lymphadenitis may also occur.
The vasoproliferative diseases BA and bacillary peliosis (BP) occur preferentially in
immunocompromised patients. BA may occur with either B. henselae or B. quintana
infections; however, BP is associated only with B. henselae (48). BA is a proliferative
disorder of the vascular endothelium resulting in the formation of tumorous lesions on the
skin (BA) and internal organs (BP) (86).
3

B. henselae Pathogenesis
Bartonella spp.are unique among bacteria for causing angioproliferation.
Endothelial cells appear to be important during BA and BP as the lesions contain bacteria
in direct contact with the endothelium. Histological examination of BA lesions has also
revealed infiltration by polymorphonuclear leukocytes and macrophages. B. henselae
pathogenesis can be divided into the effects of pro-inflammatory activation in the
endothelial cell, autocrine promotion of proliferation in endothelial cells, inhibition of
endothelial cell apoptosis, stimulation of endothelial cell proliferation, and paracrine
effects from infection of macrophages and epithelial cells.

B. henselae-Induced Pro-Inflammatory Activation
NFκB is a target for pathogens that either promote or inhibit inflammation. NFκB
activation in endothelial cells is characterized by surface expression of adhesion
molecules such as E-selectin and intracellular adhesion molecule-1 (ICAM-1) and the
release of Interleukin-8 (CXCL8, CXCL8). During B. henselae infection of endothelial
cells, endothelial cell adhesion molecules are upregulated and NFκB is activated (32).
ICAM-1 expression is also upregulated on HUVEC in response to infection (60). While
many pathogens induce inflammation, only Bartonella spp. possess the ability to cause
vasoproliferation. The role of the inflammatory response in B. henselae pathogenesis is
not well understood; however, the bacteria may utilize this mechanism to attract key
regulators of angiogenesis such as macrophages to the sites of infection, which secrete
pro-angiogenic molecules and growth factors.
4

B. henselae-Induced Endothelial Cell Survival and Proliferation
Proliferation of endothelial cells is an important step during angiogenesis. B.
henselae causes proliferation and migration of endothelial cells in vitro (20). B. henselae
also causes enhanced survival of endothelial cells through inhibition of apoptosis. This
mechanism consists of an inhibition of caspases 3 and 8 (43). Some aspects of B.
henselae-induced endothelial cell proliferation are controversial and poorly defined. For
example, some argue that direct contact with the bacterium is needed for proliferation,
since the angiogenic factor of B. henselae was localized to the particulate fraction of the
bacterium (20). Other studies revealed that direct contact is not needed for stimulation of
endothelial cell proliferation, as the endothelial cells will proliferate if they are separated
from the bacteria by a membrane (59). Another hypothesis is that the paracrine effect of
macrophages is needed for proliferation. When supernatants from B. henselae-infected
macrophages are added to endothelial cells, the cells proliferate at a higher rate than cells
incubated with uninfected macrophage supernatants (71). These data revealed a role for
the macrophage during infection as the macrophage produced potent endothelial growth
factors in response to B. henselae infection. The effect of inhibition of apoptosis versus
actual cell proliferation has also been debated (43, 77). These differences may be due to
different passages of bacteria used, differing multiplicities of infection (MOIs), and
different phases of the bacteria. Despite the presence of many conflicting ideas,
henselae causes angiogenesis through the culmination of a multitude of factors.
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B.

Paracrine Effectors During B. henselae–Induced Angiogenesis
Peripheral cells are also key regulators of angiogenesis. During B. henselae
infection, polymorphonuclear lymphocytes and macrophages are present in the
angiogenic lesions from BA (49, 50, 64). Epithelial cells as well as macrophages
produce VEGF in response to infection with B. henselae (41, 71, 77), which most likely
also contributes to vascular proliferation during B. henselae infection. CXCL8 is also
produced by B. henselae-infected epithelial cells (71, 77). These paracrine factors may
also play a vital role in B. henselae induced endothelial cell proliferation and
angiogenesis. A model of autocrine and paracrine effects on endothelial cells during B.
henselae infection, which shows the relative contributions of peripheral and host cells in

B. henselae-induced angiogenesis, is depicted in Figure 2 (71).

B. henselae Virulence Factors
The recent sequencing of the B. henselae genome has opened many new
investigations into B. henselae virulence factors. While earlier investigations identified
some putative virulence factors, such as outer membrane proteins (OMPs) and secreted
factors, further identification and mutagenesis of new and important virulence factors has
been facilitated recently. Recently identified or characterized virulence factors include
the Type IV secretion system (TFSS), lipopolysaccharide (LPS), GROEL, and BadA.

6

Figure 2. Model of paracrine and autocrine mechanisms of B. henselaemediated angiogenesis. B. henselae is able to adhere to and invade human
macrophages (mac) and induce production of VEGF. This secreted VEGF
functions in a paracrine manner and acts as an endothelial cell mitogens when it
binds to its receptors on endothelial cells. Infection of endothelial cells (EC) with
B. henselae may serve to further enhance proliferation by NFκB activation through
upregulation of adhesion molecules such as E-selectin and ICAM-1. Also,
chemokines may be produced upon endothelial cell infection which would attract
macrophages leading to enhanced growth factor signaling. In addition, caspases
are inhibited in infected endothelial cells leading to enhanced endothelial cell
survival (Resto-Ruiz et.al., 2002).
7

TFSS
TFSS are multicomponent transport systems of gram-negative bacteria. They can
mediate transfer of diverse factors, from effector proteins to DNA. The B. henselae
TFSS is encoded by the virB operon. The virB operon is induced during endothelial cell
infection (79). It has been recently determined that the TFSS encoded by the virB operon
mediates invasion, proinflammatory activation, and anti-apoptotic protection of
endothelial cells (77). However, at higher MOIs (larger than 50) the TFSS has a
cytotoxic effect on the endothelial cell. Thus the proteins coded by virB are important for
endothelial cell survival and invasion. This does not necessarily exclude the possibility
of a factor which mediates proliferation. Recently a model of the TFSS apparatus was
suggested which includes interactions between the VirB2 pilus-associated protein and
VirB3 and VirB5 (Fig. 3) (81).
Recently, the proteins which are translocated by the TFSS machinery were
identified as Bartonella effector proteins (Beps) A-G (80). Also, the VirD4 TFSS
coupling protein was identified. BepD is translocated into HUVECs in a VirB/VirD4
dependent manner. The endothelial cell response to B. henselae with a deletion of the
virB4 includes a decrease in NFκB activation, endothelial cell survival, and bacterial
invasion (77). B. henselae with deletions of bepA-G or virD4 induced an endothelial
response similar to that elicited from the endothelial cells infected with the virB4 deletion
mutant (80).

8

Figure 3. Structure of TFSS apparatus of B. henselae. The proteins coded by the
virB operon of B. henselae are thought to assemble as depicted here. VirB2 is
thought to be the main conduit through which proteins are transported, which is
driven by the VirB11 ATPase. VirB4 binds to itself as well as VirB10. VirB10
interacts with both VirB8 and VirB9. VirB5 and VirB3 exhibit the strongest
interaction (Shamaei-Tousi et. al., 2004).
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Outer membrane proteins (OMPs)
The outer membrane of gram-negative bacteria serves as an interface between the
host cell and the pathogen. B. henselae expresses a variety of outer membrane
components, including lipopolysaccharide and a hemin-binding protein (HbpA),
immunoreactive antigens, and a red blood cell invasion protein (IalB) (17). OMPs of 43kDa and 66-kDa molecular masses bound HUVEC membrane components (14). B.
henselae OMPs are important for pathogenesis (14, 32) and they have been implicated in
an NFκB-dependent proinflammatory activation of endothelial cells (32). OMPs activate
HUVEC dose-dependently as measured by E-selectin and ICAM-1 protein expression
(32). They also bind HUVEC membrane proteins and may be important for bacterial
adhesion and entry (14).

Bartonella Adhesin A (BadA)
Until recently, a putative Type IV pilus on the surface of B. henselae was
presumed to exist (9). Transmission electron microscopy of B. henselae strains showed
the presence of a pilus-like structure on the surface of the bacterium (9). This “pilus”
mediates VEGF secretion from macrophages and host cell adhesion (41). The presence
of the pili correlates with the “rough” phenotype of B. henselae. Recently, when the B.
henselae genome was published (3) it was clear that the gene for the putative Type IV
pilus was not present. Subsequently, the projections were determined to be homologous
to the non-fimbrial adhesin Yersinia adhesion A (YadA) and were renamed BadA
accordingly (72). Non-fimbrial adhesins are non-pillin structures which contain a
connector domain, a fibrous stalk, and a C-terminus anchoring domain (69). BadA
10

mediates interaction of B. henselae with extracellular matrix proteins (ECM). In
addition, BadA activates an important mediator of angiogenesis, hypoxia inducible factor
(HIF-1), and elicits an anti-BadA immune response in mice and rabbits (72). Thus BadA
is important for B. henselae infection and also may serve as a clinical marker for
infection (72).

Lipopolysaccharide (LPS)
Although LPS is usually considered a pathogenic factor in Gram-negative
bacteria, the LPS from B. henselae exhibits remarkably low endotoxicity. Bacteremic
patients display no signs of septic shock. Unique components of the LPS structure
include a pentaacyl Lipid A and a small inner core composed of an α-(2→4)-linked Kdo
disaccharide with one glucose residue attached (97). In addition, B. henselae LPS does
not signal through TLR4 or TLR2 (97). This low endotoxicity is consistent with other
intracellular bacteria such as Legionella and Chlamydia spp.

GroEL
The heat shock response of B. henselae begins at temperatures of 37°C, human
body temperature. The heat shock response includes production of GroEL, a 60 kDa
protein; GroES, a 10 kDa protein; and DnaK, a 70 kDa chaperonin (35). GroEL from B.
bacilliformis is mitogenic for HUVEC (63). B. henselae GroEL, although less potent, is
also mitogenic for HUVEC (63). Antibodies to GroEL inhibit proliferation of HUVEC in
response to B. bacilliformis lysate. GroEL was also present as a secreted protein (63).

11

Angiogenesis

Overview
Pathogenic (tumor or inflammatory) angiogenesis provides a survival mechanism
for the tissues of tumors and tumor-like lesions (30). Angiogenesis is a multistep process
during which the vessel wall disassembles, the basement membrane is degraded by
matrix metalloproteinases (MMPs), endothelial cells migrate and invade the extracellular
matrix, endothelial cells proliferate, and a capillary lumen is formed. Angiogenesis
requires cooperation between cells, cytokines, growth factors, and matrix components. A
sensitive balance between angiostatic and angiogenic factors must exist in order to
control angiogenic activity; however in tumors and tumor-like lesions, this tightly
regulated system is upset (36). Angiogenesis is associated with conditions that involve
inflammatory cell infiltrate (34), such as cancer, papopavirus infection, and herpesvirus
infection (7, 15, 28, 55, 61). Angiogenesis and inflammation coordinate through
common stimuli for endothelial cells and leukocytes; these stimuli include chemokines.
Angiogenic chemokines exert a direct effect on the endothelium and an indirect effect on
angiogenic-factor expressing leukocytes (68, 88). Chemokines are induced by TNF or
IL-1 or by interaction with bacterial pathogens and recruit leukocytes to sites of
inflammation.
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Chemokines – MCP-1
Monocyte-macrophage chemoattractant protein-1 (MCP-1) is a potent and
specific monocyte agonist and chemoattractant (33, 96) which is produced by endothelial
cells, smooth muscle cells, and macrophages in response to various stimuli, including
LPS (93). MCP-1 stimulates chemotaxis of monocytes and macrophages to sites of
inflammation (51). MCP-1 can also directly promote angiogenesis (68, 88). Thus MCP1 could play dual roles in B. henselae-induced angiogenesis by acting in an autocrine
manner on endothelial cells to promote angiogenesis, while recruiting macrophages, the
effector cell in the model, to the site of infection.

Chemokines – CXCL8
CXCL8 is a member of a family of 8 structurally related chemokines that have
been shown to induce angiogenesis. CXCL8 augments angiogenesis through enhanced
endothelial cell survival, proliferation, and MMP production (52, 53). CXCL8 receptors
CXCR1 and CXCR2 are widely expressed on normal and tumor cells (38, 84, 85, 95) and
have been observed on endothelial cells (67, 74). These receptors also play a role in
proliferation of endothelial cells (46).

Ca2+ Signaling
Calcium homeostasis may regulate important cellular functions including
activation of signal transduction pathways, proliferation, invasion, and differentiation
(26, 65, 75, 87). Ca2+ plays a key role during angiogenesis; however, the mechanisms
involved are not fully explained (2). Depletion of intracellular pools of Ca2+ and not
13

cytosolic Ca2+ levels inhibits proliferation and migration of human vascular smooth
muscle cells (10, 83). In addition, inhibition of intracellular Ca2+ pools with thapsigargin
inhibits angiogenesis in the rat isolated aorta (82). Intracellular Ca2+ pools are crucial
mediators of angiogenesis.

B. henselae and Angiogenesis
B. henselae-induced angiogenesis is reminiscent of tumor angiogenesis. B.
henselae-induced angiogenesis represents a paradigm for pathogen-triggered tumor
formation (22). Recently, the steps for B. henselae-induced angiogenesis have been
clarified to most likely include (i) an NFκB-dependent proinflammatory activation, (ii)
inhibition of endothelial cell apoptosis, (iii) direct endothelial cell proliferation, and (iv)
growth factors produced from peripheral cells.
During angiogenesis, endothelial cells migrate and proliferate, then organize into
vessels. As well as promoting endothelial cell proliferation, B. henselae causes
angiogenesis in vitro. Kirby et. al. demonstrated that B. henselae promotes survival of
endothelial cords and promotes invasion, survival, and differentiation in a collagen
matrix (42). Thus in addition to inhibition of apoptosis and endothelial cell proliferation,
B. henselae promotes capillary tube formation. Unfortunately, no small animal model of
B. henselae-induced angiogenesis has been successfully developed. Zhang et. al.
developed an animal model for B. quintana infection utilizing rhesus macaques (Macaca
mulatto) (98). This model mimics the high-titer bacteremia in humans. A small animal
model would allow for functional in vivo studies with bacterial mutants, further defining
the roles of virulence factors in an in vivo environment.
14

B. henselae-induced angiogenesis represents a unique phenomenon in which a
bacterium induces angiogenic lesions. One possible rationale for pathogen-induced
angiogenesis during Bartonella infections is that the pathogen may improve its survival
by propagation of its host cell. Vascularization during infection is exclusive for
Bartonella spp. While many bacterial virulence factors have been characterized, the
effects of these factors on the host cell are unknown. There are most likely numerous
factors culminating in the vascular lesions that are a characteristic of BA. However,
specific investigations into the direct effect of the bacterium on human endothelial cells
may clarify pathogenic mechanisms of angiogenesis.

15

Objectives
B. henselae causes angiogenic lesions in the immunocompromised, a
phenomenon unique to Bartonella spp. These lesions contain bacteria in direct contact
with the endothelium as well as infiltrating macrophages and polymorphonuclear
leukocytes. Macrophages secrete VEGF in response to B. henselae infection, thus they
are thought to be quite important during infection. However, the bacteria induce
endothelial cell proliferation in the absence of macrophages as well, so while VEGF
signaling is probably important in vivo, there may also be direct stimulation of
proliferation by the bacterium. Since the bacterial genome was published recently, there
has been much progress in identification and characterization of virulence factors.
However, the endothelial mechanisms contributing to angiogenesis during B. henselae
infection have not been fully clarified. This study was developed to identify important
endothelial cell mediators of angiogenesis during B. henselae infection and to identify the
mechanisms involved in the upregulation of these factors. Investigations into endothelial
cell contributions during B. henselae–induced angiogenesis may reveal the factor or
factors responsible for angioproliferation. A review of the current literature led to the
following hypothesis:

B. henselae causes upregulation of pro-angiogenic factors during infection of
endothelial cells, which contributes to the overall pathogenesis of B. henselae.
16

In order to refute or support this hypothesis, the following objectives were formulated:

1. To determine if B. henselae upregulates macrophage chemoattractant protein-1
production and expression in endothelial cells and the mechanism by which this occurs.

2. To determine the role of CXCL8 in B. henselae-induced endothelial cell proliferation,
survival, and capillary tube formation.

3. To determine the effect of B. henselae secreted proteins on endothelial cell
proliferation.

17

Materials and Methods

Bacterial Strains.
Bartonella henselae Houston-1 (ATCC 49882) (70) strain was grown on
chocolate agar prepared with heart infusion agar base (Difco, Detroit, MI) supplemented
with 1% bovine hemoglobin (Beckton Dickinson, Cockeysville, MD). Bacterial cultures
were maintained at 37°C and 5% CO2 and humidity to saturation. For certain
experiments, bacteria were heat-killed at 100°C for 30 minutes as described previously
(71). Escherichia coli JM109 strain was grown in Luria-Bertani broth or agar (Difco).

Cell Lines.
The immortalized human microvascular cell line (HMEC-1) (1) was cultured in
MCDB131 cell culture media (Gibco BRL, Grand Island, NY) supplemented with 10%
fetal calf serum (FCS) (Hyclone Laboratories, Logan, UT), 10 ng/ml epidermal growth
factor, 1.461 g/L L-glutamine, 1 µg/ml hydrocortisone, 50 µg/ml penicillin-streptomycin,
2.5 µg/ml amphotericin B (Sigma-Aldrich, St. Louis, MO), 2 mg/ml sodium bicarbonate,
and 10 mM HEPES (Mediatech, Herndon, VA). Human THP-1 monocytes (90) were
cultured in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10 % FCS, 5 µM 2mercaptoethanol (Sigma-Aldrich), 10 µg/ml vancomycin (Sigma-Aldrich), and 1 µg/ml
amphotericin B. Human umbilical vein endothelial cells (HUVEC) were obtained from
18

Clonetics Corporation (San Diego, CA) and were cultured in EGM (Clonetics). HepG2
cells were obtained from American Type Culture Collection (Manassas, VA) and were
cultured in MEM containing 10% fetal calf serum, 1.5 g/L sodium bicarbonate, 0.1 mM
non-essential amino acids, and 1.0 µM sodium pyruvate. Cells were maintained at 37°C
and 5% CO2 and humidity to saturation. HUVEC were used in experiments at passages
from 4 to 7.

HMEC-1 Infections.
Prior to infection, the culture medium containing antibiotics was removed from
cell cultures and replaced with media without antibiotics or growth factors. Cells were
permitted to adapt overnight. B. henselae Houston-1 were harvested from chocolate agar
and suspended in cell culture media, then concentration of bacteria was determined
spectrophotometrically as described previously (44). Briefly, at OD600, a reading of 0.5
correlates with 109 colony forming units (cfu)/ml. B. henselae were added to cells at the
multiplicity of infection (MOI) indicated. Cells were co-cultured with Houston-1 for
various timepoints.
For E. coli co-cultures, JM109 were harvested into cell culture medium and added
to cells at a density of 100 E. coli cells per HMEC-1, also determined
spectrophotometrically. During the experiments with longer time courses and during
inhibition assays, E. coli LPS (Sigma-Aldrich) was used as a positive control for MCP-1
production in order to keep HMEC-1 alive as E. coli JM109 infection was found to be
cytotoxic for HMEC-1 at later time points.
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Infections for CXCL8 ELISA.
To generate supernatants for the analysis of CXCL8 secretion, HUVEC, HepG2,
HMEC-1, or THP-1were placed into 24-well tissue culture plates (Costar, Cambridge,
Mass.) at 90% confluency. THP-1 were differentiated by overnight incubation with 1 µM
vitamin D3 (Sigma-Aldrich). Nonadherent cells were removed by washing. Cells were
infected with the Houston-1 strain of B. henselae as described previously using the
appropriate cell culture medium with no antibiotics (71). For the downstream analyses
real-time PCR and capillary tube formation, the infections and incubations post-infection
were carried out under serum-free conditions. Cells were infected at indicated MOIs.

CXCL8 ELISA.
To determine CXCL8 levels in supernatants from B. henselae-infected cells, the
DuoSet ELISA development systems (R&D Systems, Minneapolis, Minn.) for human
CXCL8 was used according to the manufacturer's directions. The 3,3',5,5'tetramethylbenzidine Liquid Substrate System (Sigma-Aldrich) was added and left for 20
min. The horseradish peroxidase reaction was stopped with 2 N sulfuric acid. ELISA
plates were analyzed using a µQuant plate reader (Bio-Tek, Winooski, VT.) at 450 nm.
HUVEC proliferation assay. HUVEC were seeded in 96-well plates at 1x103 cells per
well in media without antibiotics and allowed to adapt overnight. Cells were infected the
following day with Houston-1 at an MOI of 50 or incubated with recombinant human
CXCL8 (100 ng/ml, R&D Systems). Anti-human CXCL8 (10 µg/ml) or an isotype
control (mouse IgG1, 10 µg/ml) were added to cell media during infections. After 72
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hours, cells were fixed and examined with an inverted microscope and digital pictures
were taken with a Kodak DC290. Cells were examined for qualitative differences in
number. In addition, cells were counted in 5 high-powered fields per well and averaged.

LPS and TLR Inhibition Assays.
Polymyxin B sulfate (Sigma-Aldrich) was used to neutralize the bacterial LPS in
some experiments. Houston-1 or E. coli JM109 or purified E. coli LPS was incubated
with 30 µg/ml polymyxin B sulfate for 1 hour at 37°C and 5% CO2 before adding to
HMEC-1. In some experiments, HMEC-1 were preincubated with a mouse monoclonal
antibody (HTA 125) specific for toll-like receptor-4 (TLR-4) (e-Bioscience, San Diego,
CA) in order to determine if TLR-4 signaling was required for MCP-1 production.
HMEC-1 were pre-incubated with 20 µg/ml anti-TLR4 for one hour at 37°C with gentle
shaking, then co-cultures proceeded as usual and supernatants were collected eight hours
after addition of bacteria or LPS. Live E. coli JM109 were cultured with HMEC-1 during
some experiments in order to ensure that the TLR4 monoclonal antibody would block
activity from the LPS of live E. coli as well as from purified LPS. An isotype control
(mouse IgG2a, κ) (e-Bioscience) was used as a control antibody at 20 µg/ml. During
NFκB inhibition assays, HMEC-1 were incubated with 50 µM
pyrrolidinedithiocarbamate (PDTC) (Sigma) or 100 µM N-tosyl-L-phenylalanine (TPCK)
(Sigma) for one hour at 37°C with 5% CO2 before infections. Inhibitors were maintained
throughout the course of the assays.
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Semiquantitative RT-PCR –mcp1.
RT-PCR was performed on HMEC-1 co-cultured with B. henselae or E. coli at
the indicated times after infection. Total RNA was extracted with Trizol reagent (SigmaAldrich) according to manufacturer’s protocol. Total RNA was treated with RNase-fee
DNase (Ambion, Inc., Austin, TX) according to the manufacturer’s instructions.
Concentration of RNA was determined spectrophotometrically using a GeneQuant II
(Pharmacia Biotech, Cambridge, England). cDNA preparation and subsequent PCR
amplification were carried out by a One-Step RT-PCR kit (Qiagen, Inc., Valencia, CA) in
the presence of gene-specific primers and 2 µg total RNA. The PCR conditions were 1
min at 95°C, 1 min at 58°C, and I min at 72°C for 35 cycles. Primer sequences for RTPCR were as follows: β-actin forward 5’-AGAAAATCTGGCACCACACC-3’; β-actin
reverse: 5’-CCATCTCTTGCTCGAAGTCC-3’; MCP-1 forward 5’TTCTCAAACTGAAGCTCGCACTCTCGCC-3’; MCP-1 reverse: 5’TGTGGAGTGAGTGTTCAAGTCTTGGGAGTT-3’. PCR products were analyzed by
electrophoresis through 2% agarose gels and were visualized by ethidium bromide
staining. Amplicon sizes were 434 bp and 348 bp for β-actin and MCP-1 primers,
respectively. RT-PCR data were analyzed by scanning densitometry of gel bands with
Kodak 1D Image Analysis software and normalizing to β-actin signals obtained from the
same time points. RT-PCR reactions included a no template control and a no reverse
transcriptase control to exclude DNA or RNA contamination.
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RNA Extraction and Reverse Transcription.
Cells were infected at an MOI of 100 with Houston-1 or incubated with 100 ng/ml
rCXCL8. 10 µg/ml anti-CXCL8 or an isotype control was added at the time of infection.
After 24 hours, total RNA was extracted from HUVEC using TRIzol® reagent (SigmaAldrich) according to manufacturer’s protocol. Turbo DNA-free (Ambion, Austin, TX)
was used to remove remaining DNA according to manufacturer’s protocol. Two
micrograms of total RNA were transcribed with AMV reverse transcriptase (Promega,
Madison, WI) and used for real-time PCR or semi-quantitative RT-PCR.

Real-Time PCR.
Primers used for real-time PCR were as follows: β-actin forward
5′ACCAACTGGGACGACATGGAGAAA3′, β-actin reverse 5′-TAGCACAGCCTGG
ATAGCAACGTA-3′; Bax forward 5′-TCTACTTTGCCAGCAAACTGGTGC-3′, Bax
reverse 5′-TGTCCAGCCCATGATGGTTCTGAT-3′; Bcl-2 forward 5′-ATTTCCTGCA
TCTCATGCCAAGGG-3′, Bcl-2 reverse 5′-TGTGCTTTGCATTCTTGGACGAGG-3′.
β-actin was used as the housekeeping gene control. Real-time PCR was performed with a
Bio-Rad iQ iCycler Detection System (Bio-Rad Laboratories, Ltd.) with iQSYBR Green
supermix (Bio-Rad Laboratories, Inc., Hercules, CA). Reactions were performed in a
total volume of 25 µl with 400 nM concentrations of primers. Reactions consisted of 10
minutes at 95°C, 45 cycles of 15 s at 95°C, 15s at 58°C, and 30 s at 72°C. Melt curve
analysis was used to determine PCR specificity. Melt curve analysis was run with 80
cycles of 10 s at 55°C with each cycle raising 0.5°C. All reactions were carried out in at
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least duplicate for each sample. The standard curve method was used to determine
amounts of each transcript. Relative expression of Bcl-2 or Bax was determined by
dividing amount (ng) of Bax or Bcl-2 by amount of β-actin in each sample. Relative
induction was determined by normalizing the relative expression of the uninfected
control samples to 1. All experiments included no template controls and untranscribed
(noRT) RNA controls.

Semiquantitative RT-PCR – cxcr1,cxcr2.
Reverse transcription-PCR (RT-PCR) was performed on HUVEC 24 hours after
infection. Total RNA was extracted as described above. cDNA preparation and
subsequent PCR amplification were carried out with a One-Step RT-PCR kit (QIAGEN,
Inc., Valencia, CA) in the presence of gene-specific primers and 2 µg total RNA. The
PCR conditions were 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C for 35 cycles.
Primer sequences for RT-PCR were as follows: for ß-actin forward, 5'-AGAAAA
TCTGGCACCACACC-3'; for ß-actin reverse, 5'-CCATCTCTTGCTCGAAGTCC-3'; for
CXCR2 forward, 5'-ATTCTGGGCATCCTTCACAG-3'; and for CXCR2 reverse, 5'TGCACTTAGGCAGGAGGTCT-3'. PCR products were analyzed by electrophoresis
through 2% agarose gels and were visualized by ethidium bromide staining. RT-PCR
data were analyzed by scanning densitometry of gel bands with Kodak 1D Image
Analysis software and normalizing to ß-actin signals obtained from the same time points.
RT-PCRs included a no-template control and a no-reverse-transcriptase control to
exclude DNA or RNA contamination.

24

MCP-1 ELISA.
MCP-1 levels in infected and uninfected HMEC-1 supernatants were assayed by
MCP-1 DuoSet ELISA development system (R & D Systems, Minneapolis, MN)
according to manufacturer’s protocol. The 3, 3’, 5, 5’- tetramethylbenzidine liquid
substrate system (Sigma-Aldrich) was added and the color was allowed to develop for 20
minutes. The reaction was stopped with 2N sulfuric acid. ELISA plates were analyzed
using a µQuant platereader (Bio-Tek, Winooski, VT) at 450 nm.

Isolation of B. henselae LPS.
B. henselae LPS was isolated as described previously (92). Briefly, 3-day-old
bacteria were harvested from chocolate agar and suspended in PBS. The bacterial pellet
was washed three times with sterile water. Bacteria were lysed with lysis buffer (6%
SDS, 60 mM Tris, 46% glycerol, 6% β-mercaptoethanol, 10mM dithiothreitol) at 100°C.
Proteins were digested with proteinase K treatment. These crude extracts were
concentrated by centricon YM-3 (Millipore Corp., Bedford, MA). Crude LPS was
dialyzed against sterile endotoxin-free water for four days.

Enrichment of Outer Membrane Proteins from B. henselae and Fractionation by
Molecular Weight.
B. henselae outer membrane proteins (OMPs) were enriched after inner
membranes of total membrane preparations were solubilized with sarkosyl (14, 27). The
sarkosyl-insoluble pellet was resuspended in 10 mM HEPES (pH 7.4). Protein
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concentrations were determined using the Lowry protein assay (56). 600 µg protein in
400 µl Laemmli sample buffer with 142 mM 2-mercaptoethanol were heated at 95°C for
5 minutes and separated in a single large well of a 2-dimensional 4-12% Bis-Tris
NuPAGE gel (Invitrogen, Carlsbad, CA). Four sections of the gel were excised
corresponding to 3-33kDa (OMP-1), 34-52 kDa (OMP-2), 53-97 kDa (OMP-3), and 98+
kDa (OMP-4). Each section was minced and proteins were eluted using the Model 422
Electro-Eluter (Bio-Rad, Hercules, CA) running at 30 milliamps for three hours in elution
buffer consisting of 25 mM Tris base, 192 mM glycine, and 0.1% SDS. Buffer was then
exchanged using Microcon-YM-3 filters (Millipore Corp). Protein concentrations were
determined using the Lowry protein assay (56). During some experiments, the lower
molecular weight fraction of OMPs (OMP-1) was treated with polymyxin B sulfate (30
µg/ml) or proteinase K. OMP-1 was added to proteinase K (10 µg/ml) and incubated at
55°C for 3 hours. Proteinase K was inactivated at 100°C for 15 minutes.

HUVEC Proliferation Assay.
HUVEC were seeded in 96-well plates at 1x103 cells per well in media without
antibiotics and allowed to adapt overnight. Cells were infected the following day with
Houston-1 at an MOI of 50 or incubated with recombinant human CXCL8 (100 ng/ml,
R&D Systems). Anti-human CXCL8 (10 µg/ml) or an isotype control (mouse IgG1, 10
µg/ml) were added to cell media during infections. After 72 hours, cells were fixed and
examined with an inverted microscope and digital pictures were taken with a Kodak
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DC290. Cells were examined for qualitative differences in number. In addition, cells
were counted in 5 high-powered fields per well and averaged.
Chemotaxis of THP-1 Monocytes.
Chemotaxis of THP-1 monocytes was examined with modified Boyden chambers
(Neuroprobe, Cabin John, MD) according to manufacturer’s instructions. Briefly, the
lower well of the chamber was filled with 1.2ml supernatants from uninfected, B.
henselae-infected, or E. coli-infected HMEC-1. 510 µl of THP-1 cell suspension (5 x 105
cells) were added to the upper well. A 5 µm pore size PVP-free polycarbonate membrane
(Neuroprobe) separated the two wells. Migration occurred while incubating the
chambers at 37°C and 5% CO2 with humidity for four hours. After four hours, the upper
side of the membrane was scraped with a sterile swab soaked in PBS three times to
remove non-migrated cells and the lower side of the membrane was fixed and stained
with Hema-3 Stat Pack (Biochemical Sciences, Inc., Swedesbord, NJ) according to
manufacturer’s instructions. Cells were counted in five high-powered fields per
membrane and these numbers were averaged. Cell counts ranged from 6 to 10 cells per
high-powered field, with the exception of cells migrated in response to uninfected
HMEC-1 supernatants, in which case zero to two cells were counted per microscope field
as a result of much less migration of THP-1 cells. Results are expressed as a chemotactic
index (CI), in which the average number of cells that migrated in response to uninfected
HMEC-1 supernatants was set to one. A graph of the means of CIs for three experiments
is shown.
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In vitro Capillary Tube Formation Assay.
A 96-well plate was coated with growth factor-reduced (GFR) Matrigel (BD
Biosciences, Mountain View, CA). The matrigel contained no antibodies, a control
isotype, or anti-CXCL8 (10µg/ml). The matrigel was solidified at 37°C for one hour,
after which 104 uninfected or B. henselae-infected (MOI=100) HUVEC were added to
each well. rCXCL8 (100 ng/ml) was added to some wells containing uninfected cells at
this time. After 18 hours, plates were examined for qualitative differences in capillary
tube formation and photographs were taken with a Kodak DC290 digital camera.

Generation of B. henselae Secreted Proteins (BHSP).
B. henselae were harvested from chocolate agar plates and suspended in RPMI
1640. B. henselae were allowed to continue growth in flasks in RPMI 1640 for 24 hours
at 220 rpm on an orbital shaker. After 24 hours of incubation, the suspension was
removed from the flask and spun at 2000 rpm for 10 minutes to form a soft pellet. The
supernatant was removed and passed through a 0.22 µm filtered to remove all bacteria.
The bacteria-free supernatant was then concentrated in a Centricon-Plus 20 per
manufacturer’s instructions (Millipore, Billerica, MA). Protein concentrations were
determined by bicinchoninic acid assay (Pierce, Rockford, IL). Proteins were run on a 412% NuPAGE gel (Invitrogen) and visualized by silver staining (Bio-Rad). A vehicle
control was also generated with identical methods, except that bacteria-free agar plates
were swabbed and resuspended in RPMI 1640.
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Western Blotting.
BHSP (10 µg) or vehicle control were run on NuPAGE gels and transferred to
nitrocellulose membranes in the presence of NuPAGE transfer buffer (Invitrogen)
according to manufacturer’s instructions. Alternatively, 10 µg BHSP or vehicle control
were dotted on a nitrocellulose membrane. The membranes were blocked with TBST-5%
skim milk overnight. The membranes were washed four times with TBST and then
incubated with rabbit anti-BadA (1:1000 in blocking buffer) or rabbit anti-GROEL
(1:500 in blocking buffer). The membranes were washed four times with TBST and
incubated with a goat anti-rabbit antibody conjugated to horseradish peroxidase (1:5000
in blocking buffer). The membranes were washed and bands or dots were detected using
the ECL chemiluminescent substrate (Amersham Biosciences, Buckinghamshire, UK)
and exposure to X-ray film.

Proliferation Assays with BHSP.
HUVEC were seeded in 96-well plates at a density of 103 cells per well and
allowed to attach overnight in media without antibiotics. BHSP or vehicle controls were
added in EBM containing no antibiotics at indicated concentrations. After 72 hours, the
HUVEC were photographed and 5 high-powered fields per well were counted and
averaged.
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Measurement of CXCL8 Levels from BHSP-Treated HUVEC.
HUVEC were treated with various concentrations of BHSP or medium controls.
After 24 hours, the cell culture supernatants were collected and an ELISA was used to
measure the CXCL8 levels as described under “CXCL8 ELISA”.

Ca2+ Imaging.
The calcium-sensitive dye fura2/AM was used for measuring intracellular free
calcium concentrations in HUVEC, as previously described. Cells plated on coverslips
were incubated for 1 h at room temperature in physiological saline solution (PSS)
consisting of 140 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 7.7 mM glucose, and
10 mM HEPES (pH to 7.2 with NaOH), which also contained 1 µM fura-2/AM and 0.1%
Me2SO. The coverslips were then washed in PSS (fura-2/AM-free) prior to the
experiments being carried out. PSS was applied via a rapid application system. B.
henselae secreted proteins (BHSP) were applied with a pipette to the coverslip.
Concentrated liquid culture media containing no bacteria served as a vehicle control.
A DG-4 high speed wavelength switcher (Sutter Instruments Co., Novato, CA)
was used to apply alternating excitation with 340- and 380-nm UV light. Fluorescent
emission at 510 nm was captured using a Sensicam digital CCD camera (Cooke Corp.,
Auburn Hills, MI) and recorded with Slidebook Version 3.0 software (Intelligent Imaging
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Innovations, Denver, CO) on a Pentium IV computer. Changes in [Ca2+]i were calculated
using the Slidebook 3 software (Intelligent Imaging Innovations, Denver, CO) from the
intensity of the emitted fluorescence following excitation with 340- and 380-nm light,
respectively, using the equation,

(Eq. 1)

where R represents the fluorescence intensity ratio (F340/F380) as determined during
experiments, Q is the ratio of Fmin to Fmax at 380 nm, and Kd is the Ca2+ dissociation
constant for fura-2. Calibration of the system was performed using a fura-2 calcium
imaging calibration kit (Molecular Probes, Inc., Eugene, OR) and values were determined
to be as follows: Fmin/Fmax = 23.04; Rmin = 0.31; Rmax = 8.87.

Ca2+ Inhibitors.
The intracellular Ca2+ inhibitor thapsigargin was used in some assays when
indicated. Cells were incubated for 30 minutes with 10 µM thapsigargin followed by 30
minute incubation with Fura2/AM. In some experiments, Ca2+ imaging was performed in
the absence of extracellular Ca2+ by using PSS without Ca2+. BAPTA/AM, a Ca2+
chelator, was used during some experiments to inhibit Ca2+ signaling. The cells were
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pre-incubated with various concentrations of BAPTA/AM or DMSO for 10 minutes at
37°C and then washed to remove excess BAPTA/AM or DMSO.

Statistics.
Significance was determined by a Student’s t test with two-tailed distribution. P
values less than 0.05 were considered significant. Statistical significance of Ca2+ imaging
data was determined by two-way ANOVA. All experiments were performed in triplicate.
Data are presented as a mean ± one SD.
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Results

Induction of MCP-1 Gene Expression and Protein Production.
During B. henselae infection, monocytes and macrophages infiltrate the
angiogenic lesions (49, 50, 64). MCP-1 is a C-C chemokine which recruits monocytes
and macrophages to sites of infection through binding to its CCR2B receptor (16). We
investigated the effect of B. henselae infection on MCP-1 expression and production in
HMEC-1. MCP-1 transcript levels were assayed by semi-quantitative RT-PCR at 6 and
24 hours after infection (Fig. 4). B. henselae-infected HMEC-1 had 1.6 times higher
levels of MCP-1 transcript than uninfected controls at 6 hours after infection (T6) and 1.8
times higher levels of MCP-1 transcript 24 hours after infection (T24) (Fig. 4A, B). By
48 hours after infection, the MCP-1 message levels for uninfected HMEC-1 began to
approach the MCP-1 message levels of B. henselae-infected HMEC-1 (data not shown).
This was most likely due to the absence of growth factors in culture media; after 48 hours
of culture with no growth factors, cells start to die and MCP-1 levels increase.
MCP-1 levels in supernatants of infected or uninfected HMEC-1 were analyzed at
6, 24, and 48 hours after infection by ELISA (Fig. 4C). There was a significant increase
in MCP-1 levels when HMEC-1 were infected with B. henselae for 6, 24, or 48 hours
(P<0.007). In order to determine whether the bacterial stimulating molecule was heat
stable, bacteria were heat-killed by boiling a 100°C for 15 minutes before addition to
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Figure 4. B. henselae stimulated MCP-1 induction in HMEC-1. (A) Cells were
stimulated with B. henselae or E. coli. Some bacteria were preincubated with polymyxin
B sulfate. The levels of MCP-1 mRNA in HMEC-1 were assayed by RT-PCR at 6 and
24 hours after infection (T6, T24). (B) RNA levels of MCP-1 were determined by
scanning densitometry and normalized by comparison to β-actin RNA levels (C) MCP-1
protein production was determined by ELISA at 6, 24, and 48 hours after infection.
(UN=uninfected cells; BH=B. henselae-infected cells; PB=polymyxin B sulfate; EC=E.
coli infected cells; *P<0.007, B. henselae infection compared to uninfected cells;
**P<0.007, untreated E. coli compared to E. coli treated with polymyxin B sulfate).
Results shown are one representative of three similar experiments.
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HMEC-1. When bacteria were heat-killed, MCP-1 levels were not significantly lowered
(data not shown). These data indicate that a heat-stable molecule is responsible for MCP1 production.

Induction of MCP-1 Gene Expression and Protein Production is Independent
of B. henselae LPS and Endothelial Cell TLR4.
The cell walls of Gram-negative bacteria contain LPS, which instigates a proinflammatory response from cells through signaling through TLR4. This signaling may
lead to upregulation of pro-inflammatory cytokines such as IL-1β, TNF-α, and MCP-1.
We investigated the role of B. henselae LPS in MCP-1 production from HMEC-1.
Bacteria (B. henselae or E. coli) were treated with polymyxin B sulfate before addition to
HMEC-1. Although incubation of E. coli with polymyxin B sulfate significantly lowered
MCP-1 gene expression and protein production from HMEC-1 at T6, T24, and T48
(P≤0.006), polymyxin B had little effect on B. henselae-induced MCP-1 expression and
production (Fig. 4A, B, C).
MCP-1 production can be mediated by TLR4 or TLR2 activation (89). Since
HMEC-1 express TLR2 very weakly (25), we investigated whether B. henselae-induced
MCP-1 production is mediated through TLR4 on HMEC-1. We preincubated HMEC-1
with a TLR4 mouse monoclonal antibody (HTA125) or an isotype control (mouse IgG2a,
κ), then infected with B. henselae or added E. coli LPS (100 ng/ml). Supernatants were
collected 8 hours after infection and assayed for MCP-1 by ELISA. While HTA125
reduced MCP-1 production caused by E. coli LPS (P<0.002), B. henselae-induced MCP1 production remained unchanged by the blocking antibody (P>0.900) (Fig. 5A). These
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Figure 5. MCP-1 production during inhibition assays. Supernatants were
collected 8 hours after infection and analyzed by ELISA for MCP-1 levels. (A) Cells
were incubated with anti-tlr4 (HTA125) or a control isotype (mouse IgG2a, κ) for 1
hour before infection with B. henselae or addition of E. coli LPS (100 ng/ml). (B)
HMEC-1 were cultured in the presence of the NFκB inhibitors PDTC or TPCK before
infection with B. henselae or addition of E. coli LPS (1 µg/ml). (UN=uninfected
HMEC-1; BH=B. henselae-infected HMEC-1; EC=HMEC-1 stimulated with E. coli
LPS; *P<0.002; **P<2.00 X 10-4). A representative of three experiments is shown.
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data indicate that the MCP-1 produced in response to B. henselae from HUVEC does not
involve endothelial cell TLR4 or B. henselae LPS.

MCP-1 Production Requires NFκB Activation.
The mcp1 gene has binding sites for the transcription factors NFκB and AP-1
(73). It was established that B. henselae can induce NFκB activation in endothelial cells
(32). In order to determine if the transcription factor NFκB was responsible for MCP-1
production in HMEC-1 infected with B. henselae, NFκB inhibitors PDTC and TPCK
were added to cells before infection. MCP-1 production in response to
both B. henselae infection and E. coli LPS (1µg/ml) decreased significantly in the
presence of either inhibitor (P<0.0002) (Fig. 5B). Induction of MCP-1 production by B.
henselae is NFκB dependent.

Low Molecular Weight Outer Membrane Proteins (OMP-1) from B. henselae
Induce MCP-1 Production in HMEC-1.
Since MCP-1 production in response to B. henselae infection occurs in an LPSindependent manner, we investigated whether OMPs of the bacteria stimulate MCP-1
production in HMEC-1. It has been shown that OMPs induce NFκB activation in human
umbilical cord vein endothelial cells (HUVEC) (32). Because NFκB is one of the
transcription factors that induces MCP-1 gene expression (73, 91), we investigated
whether OMPs could induce production of MCP-1 from HMEC-1. Outer membrane
proteins were enriched from B. henselae as previously described (14). The OMPs were
separated into four molecular weight fractions (see Materials and Methods), and OMPs
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were added to HMEC-1 culture at 250 ng/ml. Out of four fractions, only the lowest
molecular weight fraction (from 3-33 kDa), Fraction 1 (OMP-1), significantly increased
MCP-1 production in HMEC-1 at 6 and 24 hours after addition of OMPs (P<0.002) (Fig.
6A). OMP-1 also caused MCP-1 production from HMEC-1 in a dose-dependent manner
(Fig. 6A). Preincubation of OMP-1 with Polymyxin B sulfate did not abrogate its effect
(P>0.700) (Fig. 6B), suggesting that endotoxin contamination in the OMP-1 preparation
is not responsible for MCP-1 induction. However, proteinase K treatment significantly
lowered the effect of OMP-1 (P<0.0002), revealing that the factor in OMP-1 which
upregulates MCP-1 production is probably a protein or proteins.

Supernatants from B. henselae-Infected HMEC-1 Induce Chemotaxis of THP-1
Monocytes.
Since MCP-1 levels are heightened in response to B. henselae infection, we
investigated whether supernatants from B. henselae-infected HMEC-1 could cause
chemotactic migration of THP-1 monocytes. A modified Boyden chamber assay was
used to assess the chemotactic response of THP-1 monocytes to chemoattractants present
in the supernatant from B. henselae-infected HMEC-1. Migrated cells were fixed,
stained, and counted in 5 high-powered fields. Supernatants from uninfected HMEC-1
were used as negative controls and supernatants from E. coli-infected HMEC-1 were
used as positive controls. Supernatants from B. henselae-infected HMEC-1 induced
THP-1 chemotaxis at a level about 6 times that of supernatants from uninfected HMEC-1
(Fig. 7) and at similar levels to supernatants from E. coli-infected HMEC-1 (4 times that
of uninfected supernatants). These results indicate that the levels of MCP-1 and/or other
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Figure 6. MCP-1 production in response to OMP fraction 1. HMEC-1 were stimulated
with OMP-1 under various dosages and conditions. Supernatants were collected at 6 and 24
(T6, T24) hours after addition of OMP-1. MCP-1 levels were determined by ELISA. (A)
Dose-dependent response of HMEC-1 to various OMP-1 concentrations (B) Effects of
polymyxin B sulfate (30 µg/ml) (PB) and proteinase K (10 µg/ml) (PK) on OMP-1 induced
MCP-1 production in HMEC-1. (*P<0.002; **P<2.00 X 10-4). A representative of three
experiments is shown.
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Figure 7. THP-1 monocyte chemotaxis in response to supernatants from B.
henselae-infected HMEC. (A) Chemotaxis of THP-1 monocytes in response to
uninfected HMEC supernatants, B. henselae-infected HMEC supernatants (BH), or E.
coli-infected HMEC supernatants (EC). Results are expressed as a chemotactic index.
The number of migrated THP-1 in five microscopic fields was averaged for supernatants
from uninfected, B. henselae-infected, and E. coli-infected HMEC-1. The chemotactic
index for cells which migrated in response to uninfected supernatants was set at one, and
other samples were normalized accordingly. Results shown are the mean of three
separate experiments.
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chemokines in supernatants from infected HMEC-1 are sufficient to cause chemotaxis of
monocytes.

CXCL8 Production from a Variety of Cell Types Infected with B. henselae.
CXCL8 plays a role in angiogenesis through induction of MMP production,
endothelial cell survival, and capillary tubule formation (52). It has been reported that
CXCL8 production is enhanced from endothelial cells and epithelial cells by an NFκBdependent pathway in the presence of B. henselae (32, 77). We tested a variety of cell
types for production of CXCL8 in response to B. henselae at an MOI of 100. Two types
of endothelial cells, HMEC-1 and HUVEC (see Materials and Methods), upregulated
CXCL8 in response to B. henselae 24 hours after infection (Fig. 8A). Other cells which
may be important for B. henselae pathogenesis (hepatocytes and monocyte-derived
macrophages) were also examined for their ability to upregulate CXCL8 in response to B.
henselae. They also markedly upregulated CXCL8 during infection (Fig. 8B, C). We
have previously reported (71) that B. henselae-infected THP-1 do not enhance CXCL8
production at an MOI=500, which conflicts with the results presented here. However,
this study used Vitamin D3 for monocyte differentiation (see Materials and Methods) in
place of phorbol myristate acetate (PMA), which lowers background CXCL8 production;
thus the differences between uninfected and infected macrophages were more clearly
distinguishable.
Furthermore, we examined HUVEC for CXCL8 receptors CXCR1 and CXCR2
expression in the presence of B. henselae. While CXCR1 RNA levels were not
significantly different between uninfected and infected HUVEC (data not shown),
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Figure 8. B. henselae-induced CXCL8 production assayed by ELISA. (A) B.
henselae induced CXCL8 production from human umbilical vein endothelial cells
(HUVEC) and; human microvascular endothelial cells (HMEC-1). (B) B. henselaeinduced CXCL8 production from hepatocytes (HepG2). (C) B. henselae-induced
CXCL8 production from monocyte-derived macrophages (THP-1). (Un=Uninfected
cells; Bh=B. henselae-infected cells; *P<0.001).
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CXCR2 levels were around four times higher in B. henselae-infected cells than in
uninfected cells (Fig. 9A, B). B. henselae causes CXCL8 production from macrophages,
endothelial cells, and hepatocytes; B. henselae also induces CXCL2 expression in
endothelial cells, indicating a putative autocrine mechanism during B. henselae infection
of endothelial cells.

Effect of Blocking CXCL8 on B. henselae-Induced Endothelial Cell Proliferation.
B. henselae causes more endothelial cell proliferation at MOIs of under 50 than at
higher MOIs (77). This is most likely due to a cytotoxic effect from a factor coded by the
virB operon at higher MOIs. However, other aspects of B. henselae-induced
angiogenesis such as inhibition of apoptosis, capillary tube formation, and NFκBdependent proinflammatory activation correlate positively with bacterial numbers(42, 43,
72). Since it has been reported that CXCL8 directly mediates endothelial cell survival
and proliferation (46), we examined the role of CXCL8 in B. henselae-induced HUVEC
proliferation (Fig. 10A). Cells were incubated with B. henselae (MOI of 50) or rCXCL8
(100 ng/ml). Cells were also treated with anti-human CXCL8 or a control IgG1 (10
µg/ml). After 3 days, pictures were taken of the wells (Fig. 9A) and cells were counted
(Fig. 10B). Both B. henselae and rCXCL8 induced proliferation as compared to
unstimulated cells. The presence of a CXCL8 antibody quenched the proliferative effect
of B. henselae and rCXCL8, while an isotype control did not. These data point to a
putative role for CXCL8 during B. henselae-induced proliferation.
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Figure 9. CXCR2 expression in HUVEC. (A) RNA was extracted from uninfected
and B. henselae-infected HUVEC and subjected to semi-quantitative RT-PCR. (B)
Scanning densitometry determined the relative intensities of CXCR2 expression when
normalized to β-actin house-keeping gene expression. Relative CXCR2 induction was
measured as a ratio of CXCR2 to β-actin when this ratio in uninfected cells was
normalized to 1. (UN=uninfected HUVEC; BH= B. henselae-infected HUVEC).
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Figure 10. Effect of CXCL8 on HUVEC proliferation in response to B.
henselae. HUVEC were uninfected (UN) or infected with B. henselae (BH) or
incubated with rCXCL8 in either the presence or absence of a neutralizing antiCXCL8 antibody or an isotype control (mouse IgG1) for 3 days. (A) Digital
pictures of typical phase-contrast microscopic fields. (B) Cell proliferation
expressed as a graph of average cell number per high-powered field. *P<0.008.
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Role of CXCL8 in B. henselae-Induced Endothelial Cell Survival.
The balance between Bax (apoptotic) and Bcl-2 (anti-apoptotic) is important for
endothelial cell survival or apoptosis. We examined HUVEC infected with B. henselae
at an MOI of 100 for expression of Bcl-2 family members Bcl-2 and Bax. CXCL8
induces increased Bcl-2 expression and decreased Bax expression (53). While it has been
reported that B. henselae inhibits apoptosis of HUVEC though inhibition of caspases
(43), the Bcl-2 and Bax levels in uninfected and B. henselae-infected HUVEC have not
been previously compared. We examined Bax and Bcl-2 levels in HUVEC by real-time
PCR. We found that B. henselae-infected HUVEC had almost undetectable levels of Bax
expression and about four times enhanced Bcl-2 expression (Fig. 11A) when compared
with uninfected controls and normalized to a β-actin housekeeping gene. This increased
Bcl-2/Bax ratio probably biases the cell into an anti-apoptotic state. We examined the
role of CXCL8 on B. henselae-enhanced HUVEC survival. When anti-CXCL8 was
added to HUVEC in the presence of B. henselae, the anti-apoptotic response of the cells
decreased markedly (Fig. 11B, C). Bax levels were raised about fivefold in the presence
of anti-CXCL8 but not in the presence of control IgG1 (Fig. 11B). Conversely, Bcl-2
levels induced by B. henselae infection dropped six fold in the presence of a CXCL8
neutralizing antibody (Fig. 11C). These results reveal a possible autocrine role for
CXCL8 in B. henselae-stimulated endothelial cell survival.
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Figure 11. Effect of anti-CXCL8 on inhibition of HUVEC apoptosis induced by
B. henselae. (A) B. henselae causes enhanced Bcl-2 expression and decreased Bax
expression in HUVEC. Results are expressed as relative expression units, a ratio of
amounts of Bcl-2 or Bax transcripts to β-actin transcript amounts. (B) Bax expression
reduced by B. henselae is increased in the presence of a neutralzing antibody to
CXCL8. (C) Bcl-2 expression increased by B. henselae is decreased in the presence
of anti-CXCL8. (UN=uninfected HUVEC; BH=B. henselae–infected HUVEC;
rCXCL=rCXCL8-treated HUVEC; *P<0.01).
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Role of CXCL8 in B. henselae-Induced Capillary Tube Formation.
In vitro angiogenesis assays have revealed a pro-angiogenic response of HUVEC
to B. henselae infection (42). HUVEC infected with B. henselae seeded on a GFR
matrigel exhibited advanced capillary tube formation when compared to uninfected
HUVEC (Fig. 12). HUVEC incubated with rCXCL8 also showed enhanced capillary
tube formation. When anti-CXCL8 was present in the matrigel, the capillary tube
formation was visibly diminished (Fig. 12). The presence of an isotype control, however,
had no such effect on tube formation. These data delineate further an autocrine role for
CXCL8 during B. henselae infection.

B. henselae Secreted Proteins (BHSP) Contain GROEL and BadA.
B. henselae secreted proteins have been implicated in endothelial cell
proliferation (59). However, the TFSS encoded by the virB operon is not responsible for
endothelial cell proliferation, and is turned on only inside the endothelial cell (77, 79).
Thus in order to avoid this cytotoxic effect and study simply the effect of TFSSindependent secreted proteins, we isolated secreted proteins (SP) from B. henselae
conditioned media as described in Materials and Methods. The proteins were analyzed
by electrophoresis and tested for the presence of GROEL, a heat shock protein that is
potentially secreted, and BadA, an immunogenic adhesion (Fig. 13A, B), by western blot
and dot blot, respectively. Both proteins were present in the SP fractions. The presence
of GROEL was expected, as it has been previously found in conditioned media from B.
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Figure 12. Effect of anti-CXCL8 on B. henselae-induced capillary formation
in a GFR matrigel. HUVEC were infected with B. henselae (BH) or uninfected
(UN) and seeded on a GFR matrigel containing no antibody, a control antibody
(mouse IgG1, 10 µg/ml), or anti-CXCL8 (10 µg/ml). Uninfected HUVEC were
then either stimulated with CXCL8 (100 ng/ml) or left alone. Pictures were taken
after 24 hours.
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Figure 13. B. henselae secreted proteins (BHSP) contain BadA and GROEL.
BHSP were analyzed by western blot for GROEL (A) and dot blot for BadA (B). A
medium control (MC) served to rule out non-specific antibody binding to proteins in
the medium. Secreted proteins from a BadA mutant (∆BadA) were also used as a
negative control for the BadA dot blot.
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henselae (63). However, the presence of BadA was unexpected since it is an adhesin;
perhaps it is shed from the bacteria during liquid culture. Thus we identified two
potentially important proteins in the B. henselae secreted protein (BHSP) fraction.

BHSP Induce a Proliferative Response in HUVEC.
There has been controversy in the literature concerning whether bacteria-host cell
contact is needed for endothelial cell proliferation to occur (20, 59). Therefore we tested
the ability of BHSP to cause proliferation in HUVEC. At a concentration of 250 µg/ml,
the BHSP caused HUVEC proliferation, while a medium control (MC) at the same
concentration did not (Fig. 14A, B). The proliferative response was almost 3 times that
of untreated controls. In addition, the morphology of the cells incubated with BHSP was
similar to the morphology of HUVEC when they are infected with B. henselae at MOIs
of 50 or lower. They are elongated and display morphology consistent with proliferating
cells in the presence of VEGF (77).

BHSP Induce an Intracellular Ca2+ Response in HUVEC.
Ca2+ signals play a key role in angiogenesis and other cellular processes (2). We
tested the ability of BHSP to induce a Ca2+ rise in HUVEC. Interestingly, when 250 µg
BHSP were added to HUVEC, intracellular Ca2+ concentrations rose rapidly to 100 nM
(Fig. 15A). When a medium control was added to HUVEC, there was no Ca2+ rise (Fig.
15A). The peak Ca2+ concentrations were significantly different (P<0.05) from base
levels (Fig. 15B).
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Figure 14. BHSP cause HUVEC proliferation. HUVEC were incubated with a
medium control (MC) or BHSP (250 µg/ml) and incubated 96 hours. Cells were
viewed by inverted microscope and pictures were taken to view qualitative cell
numbers (A). Five fields per well were counted and the average number for media
controls was normalized to 1 (B).
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Figure 15. BHSP cause a Ca2+ rise in HUVEC. BHSP were added to HUVEC
mounted on a coverslip and intracellular Ca2+ was quantified as described in Materials
and Methods. (A) One HUVEC Ca2+ response to BHSP (250 µg/ml) and a medium
control (MC). (B) The average peak and baseline Ca2+ levels were compared for all
cells. (*P<0.05; results are expressed as the mean plus one standard deviation).
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BHSP Induce an Intracellular Ca2+ Response in HUVEC from Intracellular Stores.
In order to determine if the intracellular Ca2+ response from HUVEC resulted
from extracellular Ca2+ entering the cell or from Ca2+ mobilization from intracellular
stores, we tested the Ca2+ response to BHSP under various conditions. Under
extracellular Ca2+-free conditions (0 Ca2+), the Ca2+ response did not change significantly
(Fig. 16A, B) upon application of BHSP. Thus the Ca2+ response derived from inside the
cell. Next we preincubated HUVEC with 1 µM thapsigargin (THAPS), a Ca2+ ATPase
inhibitor which depletes intracellular Ca2+ stores (10, 83). In the presence of the
inhibitor, the Ca2+ levels did not increase in response to BHSP (Fig. 15A) and the peak
values of Ca2+ concentration were significantly lowered (Fig. 16B, P<0.05). Therefore
the BHSP-derived Ca2+ response in HUVEC derives from intracellular Ca2+ pools, which
have been implicated as the crucial Ca2+ pool for angiogenesis (10, 80, 83).

BHSP-Induced HUVEC Proliferation Requires Ca2+.
Given that intracellular Ca2+ is important for angiogenesis and that BHSP induce
such a high concentration of intracellular Ca2+ as well as HUVEC proliferation, we
investigated whether HUVEC proliferation induced by BHSP would still occur in the
presence of a Ca2+ chelator, BAPTA/AM. After 10 minute pre-incubation with
BAPTA/AM at concentrations of 1 µM BAPTA/AM or equivalent volumes of a DMSO
vehicle control, the cells were washed and BHSP or medium controls were added. In the
presence of BAPTA/AM, the HUVEC proliferation was reduced almost 50% (Fig. 17).
We also determined that whole B. henselae-induced proliferation is also lowered when
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Figure 16. BHSP cause a Ca2+ rise in HUVEC from intracellular stores.
HUVEC were either incubated with 1 µM thapsigargin(THAP) for 30 minutes
followed by incubation with FURA-2-AM (20 µM), or incubated with FURA-2AM and assayed in Ca2+-free conditions. BHSP were added to HUVEC and
intracellular Ca2+ was quantified as described in Materials and Methods. (A)
Responses to BHSP from cells assayed with Ca2+ present (control), cells assayed
in the absence of Ca2+ (0 Ca), and cells incubated with 1 µM thapsigargin
(THAPS). (B) The average peak and baseline Ca2+ levels were compared for all
cells. Results are expressed as the mean plus one standard deviation. (*P<0.05).
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Figure 17. Ca2+ signaling is important for BHSP-mediated HUVEC
proliferation. HUVEC were preincubated with 1 µM BAPTA/AM or a DMSO
vehicle control. A medium control (MC) or BHSP were added to HUVEC at
indicated concentrations 250 µg/ml, or cells were infected at an MOI of 50 with B.
henselae (BH). After 72 hours, cells were photographed and five high-powered
fields (HPF) were counted and averaged (*P<0.02; **P<0.04).
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HUVEC are pre-incubated with BAPTA/AM. Consequently, intracellular Ca2+ is
important for BHSP- and live B. henselae-induced HUVEC proliferation.

BHSP Induce CXCL8 Production from HUVEC.
We have determined that CXCL8 plays an autocrine role in B. henselae –induced
endothelial cell survival, proliferation, and capillary tube formation. In order to
determine if the BHSP were inducing proliferation through CXCL8 production, we tested
the ability of BHSP to induce CXCL8 production from HUVEC. When BHSP were
added to HUVEC, the CXCL8 levels increased (Fig. 18A). CXCL8 production did not
increase in the presence of a medium control. Additionally, when BAPTA/AM was
added to HUVEC before addition of BHSP, the CXCL8 levels dropped significantly (Fig.
18B). These data indicate a role for intracellular Ca2+ activity in CXCL8 production
mediated by BHSP.
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Figure 18. BHSP induce CXCL8 production from HUVEC. (A) HUVEC were
incubated with a medium control (MC) or BHSP at indicated concentrations (µg/ml)
for 24 hours. Supernatants were collected and ELISA was performed. (B) HUVEC
were preincubated with BAPTA/AM or DMSO control. BHSP or media controls
were added at shown concentrations (µg/ml) and supernatants were collected after
24 hours and ELISA was performed. *P<0.03.
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Discussion

B. henselae, the etiologic agent of CSD, is a fastidious, gram-negative, oxidasenegative, aerobic bacillus (11, 13). B. henselae infections cause a range of symptoms
from lymphadenopathy (CSD) to systemic disease. The severity of the disease tends to
relate to immune status. Immunocompromised patients such as AIDS patients, chronic
alcoholics, or immunosuppressed people can develop systemic disease. However,
immunocompetent patients may still present with systemic bacteremia, endocarditis, and
bacillary angiomatosis.
B. henselae can cause vascular proliferative lesions (5) into which macrophages
infiltrate during infection (49, 50, 64). In the paracrine and autocrine model of B.
henselae-induced angiogenesis (Fig. 2), macrophages are implicated as effector cells;
upon stimulation by B. henselae, they secrete VEGF and other endothelial cell mitogens
(71). Concurrently, endothelial cells upregulate pro-angiogenic factors such as
chemokines, inhibit apoptosis through inhibition of caspases (44), and upregulate
adhesion molecules (32) which may promote proliferation. In this study we investigated
the endothelial cell mediators of angiogenesis which are induced upon infection with B.
henselae. Specifically, we determined that B. henselae (i) upregulates MCP-1
production, which brings the effector cell macrophage into the site of infection, where it
secretes VEGF and CXCL8 which would promote angiogenesis; (ii) induces CXCL8
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production and CXCL8 receptor CXCR2 expression, which promotes angiogenesis in an
autocrine manner by enhancing endothelial cell survival, endothelial cell proliferation,
and capillary tube formation; and (iii) causes an intracellular Ca2+ rise from intracellular
pools which leads to NFκB-directed pro-inflammatory activation and endothelial cell
proliferation. These mediators of angiogenesis which are induced by the bacterium
probably play a pivotal role in B. henselae-induced angiogenesis. When the additional
factors from peripheral cells are considered, a model of B. henselae-induced angiogenesis
emerges (Fig. 19).
Macrophages and monocytes infiltrate lesions caused by BA (49, 50, 64).
Macrophages secrete VEGF upon B. henselae infection, which probably contributes to
angiogenesis during infection (41, 71). We investigated the mechanism by which the
macrophage is brought into the site of infection by examining the expression and
production of the chemokine MCP-1 from B. henselae-infected HMEC-1. MCP-1 is a
member of the C-C chemokine family and is produced and secreted by monocytes,
fibroblasts, and vascular endothelial cells. MCP-1 then interacts with its CCR2B receptor
on monocytes and macrophages to cause chemotaxis (16). MCP-1 can also directly
promote angiogenesis. When tumor cells are transfected with mcp-1 gene and injected
into a murine model, angiogenesis is stimulated (68). In addition, MCP-1 implants
induce angiogenesis in a rabbit cornea (88). During B. henselae infection, MCP-1
released from endothelial cells, most likely in addition to other factors, causes chemotaxis
of monocytes and macrophages to the site of infection, thereby promoting an angiogenic
state by recruiting the effector cell.
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Figure 19. Endothelial cell mediators of angiogenesis during B. henselae
infection. This model depicts the mediators of angiogenesis that are induced
by B. henselae from endothelial cells (EC). When ECs are infected with B.
henselae (BH), MCP-1 is produced and recruits macrophages (Mφ), which
secrete VEGF when they are infected. CXCL8 is also produced from ECs,
leading to enhanced EC survival and capillary tube formation. BH secretes
proteins (BHSP), which induce a Ca2+ spike from intracellular stores and
contribute to NFκB-dependent CXCL8 production and EC proliferation.
These mechanisms culminate in B. henselae-induced angiogenesis.
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Bacterial pathogens such as E. coli, Orientia tsutsugamushi, and Porphorymonas
gingivalis increase chemokine production and secretion (18, 45, 99). MCP-1 is induced
in HMEC-1 in response to B. henselae infection (Fig. 4). Both mRNA and protein levels
are upregulated; mRNA levels are higher than uninfected controls in B. henselae-infected
HMEC-1 at 6 and 24 hours after infection, while protein levels in infected cells are higher
at 6, 24, and 48 hours after infection. Furthermore, supernatants from B. henselaeinfected HMEC-1 caused chemotaxis of THP-1 monocytes (Fig. 7). Thus the levels of
MCP-1 produced by HMEC-1 in response to B. henselae infection in vitro are sufficient
to function as a chemoattractant for monocytes. Results also reveal that the bacterial
factor which causes MCP-1 production is probably a heat stable molecule.
The LPS of B. henselae has recently been characterized as containing a lipid A
possessing features known to reduce endotoxicity, including a pentaacyl lipid A and a
long-chain fatty acid (97). B. henselae LPS induces TLR4 1000-fold lower than
Salmonella enterica sv. Friedenau LPS (97). In addition, LPS from B. quintana, which is
likely quite similar to B. henselae LPS, induces GRO-CINC-1 in rats but not TNF in rats
or human whole blood (62). B. henselae LPS also does not induce TNF in cats. In this
study, the addition of polymyxin B sulfate to B. henselae before infection of HMEC-1 did
not reduce MCP-1 production; however, polymyxin B sulfate had a significant lowering
effect on E. coli-induced MCP-1 production (Fig. 4). These data corroborate with the
low endotoxicity of LPS from Bartonella spp. to imply a limited or nonexistent role for
LPS in B. henselae-induced MCP-1 production.
Toll-like receptors activated by various microbial products can cause expression
and production of chemokines (23, 24, 57), including MCP-1 (76). LPS, a TLR4 agonist,
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causes MCP-1 production in a TLR4-dependent manner (89). Most studies confirm that
MCP-1 production is TLR4-mediated, and usually caused by LPS in a bacterial infection.
However, recently it was discovered that TLR4-deficient and TLR4-competent mice have
the same MCP-1 response to infection by Leishmania major (6), which is known to cause
chemokine production early in infection (40). Our findings indicate that MCP-1
production in response to B. henselae infection is not TLR4-dependent (Fig. 5A). In
contrast, E. coli LPS-induced MCP-1 production was lowered in the presence of a TLR4
monoclonal antibody. These data suggest the possibility of an alternate pathway to TLR4
activation for the MCP-1 production from B. henselae-infected HMEC-1. Furthermore,
these results again exclude B. henselae LPS from a role in MCP-1 production. HMEC-1
express TLR1, TLR3, TLR4, and TLR5 but express TLR2 very weakly, which is why
they are unresponsive to TLR2 ligands (25). Thus the MCP-1 production investigated in
this study is probably not TLR4- or TLR2-mediated. Other TLR or similar receptor
pathways must be investigated to pinpoint the exact mechanism of MCP-1 induction in
HMEC-1 in response to B. henselae.
The mcp-1 gene contains binding sites for both NFκB and AP-1 (73, 91), and both
transcription factors have been implicated in mcp-1 expression (18, 94). It has been
established that B. henselae induces NFκB-dependent upregulation of adhesion molecules
in HUVEC independent of LPS (32). The findings from our study suggest the
independence of MCP-1 expression and protein production from B. henselae LPS. In
addition, we used two NFκB inhibitors to determine whether MCP-1 protein production
requires NFκB activation. Diverse NFκB inhibitors have been used with HMEC-1
previously in similar experiments (18). PDTC is an antioxidant that inhibits the
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phosphorylation of IκB (66, 78) and TPCK inhibits proteosome-dependent degradation of
inhibitory peptides (58). Consequently, through the use of these inhibitors, we
demonstrated that MCP-1 production caused by B. henselae in HMEC-1 is NFκBdependent (Fig. 5B).
OMPs of B. henselae are important for pathogenesis (14, 32). Data presented
here reveal the ability of B. henselae Houston-1 OMPs, specifically OMPs of low
molecular weight, to enhance production of the C-C chemokine MCP-1 from HMEC-1
(Fig. 6A). This upregulation is again independent of LPS, as shown by incubation of
OMP-1 with polymyxin B sulfate before addition to HMEC-1 (Fig. 6B). These data
point to a heat-stable low molecular weight OMP of B. henselae Houston-1 that
contributes at least in part to B. henselae-induced MCP-1 production from endothelial
cells. Further studies are needed in order to specify the putative OMP that causes MCP-1
upregulation in endothelial cells.
We have described upregulation of gene expression and protein production of the
chemokine MCP-1 in response to B. henselae infection. This stimulation of HMEC-1 is
independent of B. henselae LPS and toll-like receptor 4 but dependent on NFκB activity.
MCP-1 produced by infected HMEC-1 most likely contributes to the ability of
conditioned media from these cells to induce monocyte chemotaxis. The recruitment of
macrophages by MCP-1 produced from infected endothelial cells could have broad
implications on mechanisms of angiogenesis during this infection. Specifically, the
macrophage effector cell which secretes VEGF and other angiogenic factors is brought to
the site of infection. Pathogenic angiogenesis provides actively growing target cells for
B. henselae in an enriched vascularized microenvironment, and while the specific role of
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MCP-1 induction in this phenomenon is not completely understood, we suggest that
recruitment of the monocyte/macrophage effector cell is an important component of the
pathway.
Angiogenesis is a complex process involving several key steps. These steps
include (i) inhibition of endothelial cell apoptosis, (ii) endothelial cell proliferation, (iii)
breakdown of the extracellular matrix by MMPs, and (iv) capillary tube formation.
CXCL8 can promote each of these steps. Since B. henselae upregulates CXCL8
production from endothelial cells (21, 71), we investigated a putative autocrine role for
CXCL8 in B. henselae-induced angiogenesis.
There are conflicting reports on whether endothelial cells actively proliferate or
whether they simply exhibit enhanced survival in the presence of B. henselae (43, 77).
Endothelial cell proliferation in BA most likely comes from a combination of inhibition
of apoptosis and mitogenic stimulation. In addition, endothelial cell proliferation and
angiogenesis probably result from the effects of the bacterium on both the endothelial
cells and peripheral cells such as epithelial cells and macrophages (41, 71). While this
particular study focuses on the autocrine role of CXCL8, a paracrine role should not be
overlooked as many cell types produce CXCL8 after infection with B. henselae (Fig. 8).
Furthermore, the bacterium causes an upregulation of expression of one of the CXCL8
receptors, CXCR2 (Fig. 9). This may represent a mechanism by which the effects of
CXCL8 on the endothelial cell are enhanced because the receptor is present at elevated
levels. When the fact that CXCL8 production is upregulated from endothelial and other
cells is combined with the information that CXCR2 expression is also enhanced during
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endothelial cell infection, a model emerges whereby CXCL8 signaling is extremely
elevated in the endothelial cell during B. henselae infection.
The balance between Bax and Bcl-2 is important for endothelial cell survival or
apoptosis. CXCL8 induces an increase in Bcl-2 expression and a decrease in Bax
expression, most likely favoring survival over apoptosis in endothelial cells (52). It has
been shown that B. quintana can modulate the cell-programmed death of HUVEC-C by
increasing Bcl-2 expression (54). In this study, we examined expression of two Bcl-2
family members, Bcl-2 (anti-apoptotic) and Bax (apoptotic) in HUVEC by real time RTPCR. In the presence of B. henselae, Bax is decreased and Bcl-2 is increased (Fig. 11A).
These increases and decreases are quite dramatic alone; however, when the ratio of Bcl-2
to Bax is considered, the comparison is even more drastic. This is the first report of B.
henselae mediating Bax and Bcl-2 expression in endothelial cells. In addition, the data
reveal a possible role for CXCL8 in this prevention of apoptosis since the presence of
anti-CXCL8 abrogates the higher Bcl2 levels and the lower Bax levels induced by B.
henselae (Fig. 11B, C).
These data also implicate CXCL8 as a mediator of endothelial cell proliferation
and capillary tube formation during infection. Both aspects of angiogenesis were
decreased in the presence of a CXCL8 neutralizing antibody (Figs. 10, 12). However,
other mechanisms are probably also involved in proliferation, including the activity of
growth factors such as VEGF from other cells. It has been shown that while B. henselae
cause endothelial cells to proliferate, this proliferation is inhibited at higher MOIs as a
result of a cytotoxic effect from the B. henselae TFSS (77). Our proliferation results
agreed with this phenomenon; at MOIs above 50, endothelial cell proliferation was
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decreased. However, the other aspects of angiogenesis (capillary tube formation,
enhanced endothelial cell survival, and CXCL8 production) increased at an MOI of 100
when compared to an MOI of 50 (data not shown). These results suggest that the
cytotoxic effect of the products of the virB does not have an effect on expression of Bcl-2
family members or capillary tube formation. Thus the pro-angiogenic effect of B.
henselae may consist of a complicated fusion of many host cell and bacterial factors.
Nevertheless, CXCL8 seems to play an autocrine and possible paracrine role in B.
henselae-induced angiogenesis, representing a mechanism by which the bacterium causes
upregulation of CXCL8 thereby increasing its survival by expanding its host cell
reservoir. An assessment of the contribution of each of these in vitro components toward
the overall angiogenesis mediated by B. henselae is still unfinished, and it will require
extensive in vivo and in vitro studies.
B. henselae secreted proteins (BHSP), or conditioned media, have been shown to
induce endothelial cell proliferation (59). These proteins are isolated from B. henselae
grown on chocolate agar and resuspended in liquid medium for 24 hours. There is a
cytotoxic effect from the TFSS of B. henselae, which mediates secretion of BepD into
endothelial cells (80), at MOIs above 50. When a virB mutant is used to infect HUVEC,
the proliferation is 4-fold higher than with wildtype B. henselae (77). Thus it was
determined that the TFSS triggers a cytotoxic effect in HUVEC. The virB promoter is
only active inside the cell; B. henselae containing a GFP reporter construct driven by the
virB promoter are not green outside of the cell (79). BHSP therefore contain only low
levels, if any, of TFSS-transported proteins.
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NFκB activation links the upregulation of MCP-1 and CXCL8 during B. henselae
infection. Thus we investigated upstream of NFκB activation by examining the
intracellular Ca2+ response to bacterial secreted proteins. In this study we determined that
BHSP in fact cause endothelial cell proliferation (Fig. 14) and that this proliferation is
dependent on Ca2+ signaling, since in the presence of the Ca2+ chelator BAPTA/AM
HUVEC proliferation was lowered (Fig. 17). Additionally, we demonstrated that BHSP
induce a Ca2+ elevation in HUVEC, while a medium control did not have the same effect
(Fig. 15). Furthermore, we showed that the origin of the Ca2+ response to BHSP is an
intracellular store, since the intracellular Ca2+ store inhibitor thapsigargin abolished the
BHSP-induced Ca2+ rise in HUVEC (Fig. 16).
CXCL8 is an important mediator of angiogenesis and is important for HUVEC
survival and capillary tube formation during B. henselae infection of HUVEC. Since the
BHSP induced HUVEC proliferation, we sought to ascertain whether BHSP induce
CXCL8 production from HUVEC. In the presence of BHSP, CXCL8 production was
raised about four times higher than a medium control (Fig. 18A, P<0.001). However, the
CXCL8 levels in the presence of BHSP did not increase above 100 pg/ml (Fig. 18A, B).
These CXCL8 levels are lower than those elicited by live B. henselae (Fig. 8). Thus the
question arises: Are these CXCL8 levels sufficient to cause HUVEC proliferation or is
there another proliferative pathway activated by BHSP? In fact, during proliferation
assays, HUVEC are seeded at a low density (103 HUVEC/well of a 96-well plate) in
order to allow for proliferation over 3-4 days. Thus while MOIs of live bacteria take into
account the cell numbers, the concentrations of BHSP are determined as µg/ml.
Therefore during proliferation assays, higher CXCL8 levels may be elicited as a result of
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lower numbers of cells. Unfortunately, since the HUVEC proliferate over 3 or 4 days,
measurement of CXCL8 levels would be skewed as there are more cells in BHSP-treated
wells. Additionally, the BHSP are present for 3 days and may cause more CXCL8
production over that time course. Consequently, we propose that while the CXCL8
responses to BHSP were not as robust as the response to live B. henselae, these levels
may be sufficient to cause HUVEC proliferation. CXCL8 production enhanced by BHSP
was lowered in the presence of a Ca2+ chelator BAPTA/AM (Fig. 18B). NFκB activation
can be mediated by intracellular Ca2+ signaling, and BHSP induction of CXCL8 appears
to be Ca2+-dependent.
The factor which induces the Ca2+ rise and subsequent effects is still unknown.
We determined that BHSP contain BadA and GROEL (Fig.13), both which are important
during B. henselae infection of endothelial cells (63, 72). BadA binds to the extracellular
matrix proteins collagen, laminin, and fibronectin (72). This could be responsible for the
Ca2+ rise in HUVEC. GROEL is mitogenic for endothelial cells, which may contribute to
HUVEC proliferation and CXCL8 production mediated by BHSP. The TFSS mediates
CXCL8 production in HUVEC as well (77); perhaps low levels of some of the effectors
translocated by the TFSS are present in the BHSP or the components on the bacterial
membrane are present in BHSP. Further studies are necessary to determine the factor
responsible for proliferation and CXCL8 production, including proteomic analysis of the
BHSP and functional assays of these species present in BHSP.
We propose that the BHSP experiments may evolve into an animal model of B.
henselae-induced angiogenesis. A rhesus macaque model of B. quintana infection was
developed in which the levels of bacteria mimicked human infection (98). No infection
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model in mice has been successfully developed; Arvand et.al. showed bacterial presence
up to one week after infection in C57/BL6 mice (8), after which the bacteria were
cleared. Perhaps the BHSP could be used in an angiogenic model such as an in vivo
matrigel in mice or the chicken embryo assay, which may circumvent the problems
associated with clearance of B. henselae during mice infection.
Endothelial cell mediators of angiogenesis induced by B. henselae contribute to
the overall pathology in B. henselae infection. In this study we identified three mediators
of angiogenesis induced from the endothelial cell as a result of bacterial factors: MCP-1,
which brings the macrophage effector cell into the site of infection; CXCL8, which
directly promotes angiogenesis in an autocrine manner; and intracellular Ca2+ activity,
which contributes to endothelial cell proliferation and NFκB activation. These factors
and others from peripheral cells culminate in the unique angiogenic lesions seen during
B. henselae infection in the immunocompromised. A better understanding of how B.
henselae causes angio-proliferation could lead to the development of improved
therapeutics and contribute to the understanding of interactions between intracellular
bacteria and host cells.
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